Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore U

Trial Details

NCT ID
NCT04685616
Phase
PHASE3
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Involved site radiotherapy
  • Doxorubicin
  • Bleomycin
  • Brentuximab vedotin
  • Vinblastine
  • Dacarbazine
Locations (sample)
  • Stanford, California, United States|37.42411,-122.16608
  • Miami, Florida, United States|25.77427,-80.19366
  • New York, New York, United States|40.71427,-74.00597
  • Saint Leonards, New South Wales, Australia
  • Townsville, Queensland, Australia|-19.26639,146.80569

Key Eligibility Criteria

  • Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)
  • Histologically confirmed classical Hodgkin lymphoma
  • Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any lev…
  • ECOG performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →